The provincial government is making changes to coverage for some injectable biologic medications in its Prescription Drug Program.

People who use a number of costly injectable drugs to treat conditions such as rheumatoid arthritis, multiple sclerosis, and diabetes will be forced to make the switch to a generic drug in order to keep their coverage.

Drugs include Copaxone, Enbrel, Humalog, Humira, Lantus, Lovenox, NovoRapid, Remicade, and Rituxan.

The province says generic versions of biologic medications undergo an extensive approval process by Health Canada and are ensured to be as safe and effective as the branded drug.

Those using the listed drugs will be switched to a generic brand by March 31, 2024. Patients will receive a letter from government with transition information.

Government says the switch to cheaper treatments will allow them to invest in other medications and expand the Prescription Drug Program.